Skip to main content
logo
Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
86.70
-1.40 (-1.59%)
Jul 31, 2026, 4:08 PM HKT

Innovent Biologics Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
813.57-94.63-1,028-2,179-2,729
Depreciation & Amortization
596.84417.46310.22276.79202.17
Other Amortization
4.482.3174.8942.642.58
Loss (Gain) From Sale of Assets
0.5722.990.95-0.060.71
Asset Writedown & Restructuring Costs
31.52632.57115.36--
Loss (Gain) From Sale of Investments
-4.56-179.03-30.81-5.1-125.02
Loss (Gain) on Equity Investments
96.7941.01---
Stock-Based Compensation
662.7556.52574.2469.49501.57
Other Operating Activities
-145.43-515.93-272.47-833.19213.88
Change in Accounts Receivable
-529.43-178.52-430.62393.14-493.03
Change in Inventory
-451.46180.63358.95-105.39-643.28
Change in Accounts Payable
136.91-14.8746.93130.5774.43
Change in Unearned Revenue
7,661-31.19-138.63205.04105.43
Change in Other Net Operating Assets
1,127447.71566.77-313.45864.46
Operating Cash Flow
10,0011,287147.81-1,919-2,025
Operating Cash Flow Growth
677.06%770.73%---

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-269.88-965.67-1,119-896.9-1,066
Sale of Property, Plant & Equipment
-0.270.050.190.1
Sale (Purchase) of Intangibles
-413.39-676.42-262.35-468.6-781.88
Sale (Purchase) of Real Estate
--16.23--
Investment in Securities
-6,377-981.19-204.43-384.74-254.58
Other Investing Activities
548.311,458571.22314.87-596.15
Investing Cash Flow
-6,512-1,165-998.66-1,435-2,698

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
2,504515.571,3361,0801,463
Long-Term Debt Repaid
-2,555-1,246-948.85-392.74-278.72
Net Debt Issued (Repaid)
-50.74-730.44386.7687.431,184
Issuance of Common Stock
4,71984.312,2552,1313,951
Other Financing Activities
60.4639.5-54.5673.59-131.52
Financing Cash Flow
4,728-606.632,5872,8925,003

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-115.5912.68-6.88118.66-197.14
Net Cash Flow
8,102-472.341,730-343.2483.23

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
9,731321.36-971.58-2,816-3,090
Free Cash Flow Growth
2928.12%----
Free Cash Flow Margin
74.62%3.41%-15.65%-61.80%-72.38%
Free Cash Flow Per Share
5.590.20-0.62-1.89-2.12
Levered Free Cash Flow
3,228-17.42-907.54-2,475-2,612
Unlevered Free Cash Flow
3,27824.86-845.9-2,411-2,573

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
95.24122.43127.61104.8878.83
Cash Income Tax Paid
0.640.16-114.4266.126.44
Change in Working Capital
7,945403.76403.39309.91-91.98